Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice.
Oxidative stress is involved in the pathogenesis of atherosclerosis, and angiotensin II (AT-II) induces oxidative stress and enhances atherogenesis. Aldosterone, which has an important role in the pathology of heart failure, has recently been implicated as a mediator of AT-II biologic activities. In this study, we analyzed whether administration of the selective aldosterone blocker eplerenone to atherosclerotic apolipoprotein E-deficient (E0) mice would affect their oxidative status and atherogenesis. Apolipoprotein E-deficient mice were administered chow containing eplerenone (200 mg/kg/day) for 3 months. Blood pressure, serum and macrophage oxidative status, and aortic atherosclerotic lesion area were evaluated in mice treated with eplerenone compared with untreated mice. Eplerenone administration significantly decreased systolic and diastolic blood pressure by 12% and 11%, respectively, compared with untreated mice. Serum susceptibility to lipid peroxidation decreased by as much as 26%, and serum paraoxonase activity increased by 28% in eplerenone-treated mice compared with untreated mice. Peritoneal macrophages from eplerenone-treated mice contained reduced levels of lipid peroxides, and their macrophage oxidation of low-density lipoprotein (LDL) and superoxide ion release were significantly reduced (by 17% and 43%, respectively), compared to untreated mice. Daily injections of AT-II (0.1 mL, 10(-)7M) during the final 3 weeks of the study in eplerenone-treated mice substantially attenuated the eplerenone-mediated reduction in macrophage superoxide release and LDL oxidation. Finally, the atherosclerotic lesion area in aortas of eplerenone-treated mice was significantly reduced (by 35%) versus untreated mice, and this effect was reversed by AT-II. Administration of the selective aldosterone blocker eplerenone significantly reduced oxidative stress and atherosclerosis progression in E0 mice. These data suggest that aldosterone could have a significant pro-oxidative role in the pathogenesis of atherosclerosis.
Keidar
Shlomo
S
Lipid Research Laboratory, Technion Faculty of Medicine, Rambam Medical Center, Haifa, Israel. skeidar@rambam.health.gov.il
Hayek
Tony
T
Kaplan
Marielle
M
Pavlotzky
Elsa
E
Hamoud
Shadi
S
Coleman
Raymond
R
Aviram
Michael
M
D000450:Aldosterone / Q000097:blood; D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics*; D001161:Arteriosclerosis / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D043303:Aryldialkylphosphatase / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D000077545:Eplerenone; D016166:Free Radical Scavengers / Q000737:chemistry / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008055:Lipids / Q000097:blood; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D000451:Mineralocorticoid Receptor Antagonists / Q000737:chemistry / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D013481:Superoxides / Q000378:metabolism; D013997:Time Factors
D001057:Apolipoproteins E; D016166:Free Radical Scavengers; D008055:Lipids; D000451:Mineralocorticoid Receptor Antagonists; D013481:Superoxides; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone; D043303:Aryldialkylphosphatase